Hepatitis Monthly

Published by: Kowsar

Recombinant Nonstructural 3 Protein, rNS3, of Hepatitis C Virus Along With Recombinant GP96 Induce IL-12, TNFα and α5integrin Expression in Antigen Presenting Cells

Mohammad Reza Hajizadeh 1 , Pooneh Mokarram 1 , 2 , Eskandar Kamali sarvestani 3 , Azam Bolhassani 4 and Zohreh Mostafavi Pour 1 , 5 , *
Authors Information
1 Recombinant Proteins Lab, Biochemistry Department, Medical School, Shiraz University of Medical Sciences, Shiraz, IR Iran
2 Gastroentrohepatology Research Center, Medical School, Shiraz University of Medical Sciences, Shiraz, IR Iran
3 Immunology Department, Medical School, Shiraz University of Medical Sciences, Shiraz, IR Iran
4 Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, IR Iran
5 Faculty for Advanced Biomedical Sciences, Shiraz University of Medical Sciences, Shiraz, IR Iran
Article information
  • Hepatitis Monthly: June 01, 2013, 13 (6); e8104
  • Published Online: June 3, 2013
  • Article Type: Research Article
  • Received: September 11, 2012
  • Revised: January 6, 2013
  • Accepted: March 10, 2013
  • DOI: 10.5812/hepatmon.8104

To Cite: Hajizadeh M R, Mokarram P, Kamali sarvestani E, Bolhassani A, Mostafavi Pour Z. Recombinant Nonstructural 3 Protein, rNS3, of Hepatitis C Virus Along With Recombinant GP96 Induce IL-12, TNFα and α5integrin Expression in Antigen Presenting Cells, Hepat Mon. 2013 ; 13(6):e8104. doi: 10.5812/hepatmon.8104.

Copyright © 2013, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Baldo V, Baldovin T, Trivello R, Floreani A. Epidemiology of HCV infection. Curr Pharm Des. 2008; 14(17): 1646-54[PubMed]
  • 2. Hashempoor T, Bamdad T, Merat S, Janzamin E, Nemati L, Jabbari H, et al. Expansion of CD4+CD25+FoxP3+ Regulatory T Cells in Chronic Hepatitis C Virus Infection. Iran J Immunol. 2010; 7(3): 177-185
  • 3. Averhoff FM, Glass N, Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis. 2012; 55 Suppl 1-5[DOI][PubMed]
  • 4. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol. 2007; 5(6): 453-63[DOI][PubMed]
  • 5. Samimi-Rad K, Toosi Nasiri M, Masoudi-nejad A, Najafi A, Rahimnia R, Asgari F, et al. Molecular epidemiology of hepatitis C virus among injection drug users in Iran: a slight change in prevalence of HCV genotypes over time. Arch virol. 2012; 157(10): 1959-65
  • 6. Zarkesh-Esfahani SH, Kardi MT, Edalati M. Hepatitis C virus genotype frequency in Isfahan province of Iran: a descriptive cross-sectional study. Virol J. 2010; 7: 69[DOI][PubMed]
  • 7. Feinstone SM, Hu DJ, Major ME. Prospects for prophylactic and therapeutic vaccines against hepatitis C virus. Clin Infect Dis. 2012; 55 Suppl 1-32[DOI][PubMed]
  • 8. Hofmann WP, Sarrazin C, Zeuzem S. Current standards in the treatment of chronic hepatitis C. Dtsch Arztebl Int. 2012; 109(19): 352-8[DOI][PubMed]
  • 9. Pawlotsky JM. New antiviral agents for hepatitis C. F1000 Biol Rep. 2012; 4: 5[DOI][PubMed]
  • 10. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature. 2005; 436(7053): 946-52[DOI][PubMed]
  • 11. Brass V, Moradpour D, Blum HE. Molecular virology of hepatitis C virus (HCV): 2006 update. Int J Med Sci. 2006; 3(2): 29-34[PubMed]
  • 12. Jiao X, Wang RY-H, Feng Z, Hu G, Alter HJ, Shih JW-K. DNA immunization encoding the secreted nonstructural protein 3 (NS3) of hepatitis C virus and enhancing the Th1 type immune response*. J viral hepat. 2004; 11(1): 18-26
  • 13. Gnjatic S, Sawhney NB, Bhardwaj N. Toll-like receptor agonists: are they good adjuvants? Cancer J. 2010; 16(4): 382-91[DOI][PubMed]
  • 14. Bolhassani A, Rafati S. Heat-shock proteins as powerful weapons in vaccine development. Expert Rev Vaccines. 2008; 7(8): 1185-99[DOI][PubMed]
  • 15. Tsan MF, Gao B. Heat shock proteins and immune system. J Leukoc Biol. 2009; 85(6): 905-10[DOI][PubMed]
  • 16. Chen C, Jia X, Meng S, Liu W. [Overview of Gp96 mediated immunity]. Sheng Wu Gong Cheng Xue Bao. 2011; 27(5): 704-11[PubMed]
  • 17. Teng LS, Jin KT, Han N, Cao J. Radiofrequency ablation, heat shock protein 70 and potential anti-tumor immunity in hepatic and pancreatic cancers: a minireview. Hepatobiliary Pancreat Dis Int. 2010; 9(4): 361-5[PubMed]
  • 18. Ulanova M, Gravelle S, Barnes R. The role of epithelial integrin receptors in recognition of pulmonary pathogens. J Innate Immun. 2009; 1(1): 4-17[DOI][PubMed]
  • 19. Takada Y, Ye X, Simon S. The integrins. Genome Biol. 2007; 8(5): 215[DOI][PubMed]
  • 20. Acharya AP, Dolgova NV, Moore NM, Xia CQ, Clare-Salzler MJ, Becker ML, et al. The modulation of dendritic cell integrin binding and activation by RGD-peptide density gradient substrates. Biomaterials. 2010; 31(29): 7444-54[DOI][PubMed]
  • 21. Mohit E, Bolhassani A, Zahedifard F, Taslimi Y, Rafati S. The contribution of NT-gp96 as an adjuvant for increasing HPV16 E7-specific immunity in C57BL /6 mouse model. Scand J Immunol. 2012; 75(1): 27-37[DOI][PubMed]
  • 22. Bolhassani A, Zahedifard F, Taslimi Y, Taghikhani M, Nahavandian B, Rafati S. Antibody detection against HPV16 E7 & GP96 fragments as biomarkers in cervical cancer patients. Indian J Med Res. 2009; 130(5): 533-41[PubMed]
  • 23. Mihailova M, Fiedler M, Boos M, Petrovskis I, Sominskaya I, Roggendorf M, et al. Preparation of hepatitis C virus structural and non-structural protein fragments and studies of their immunogenicity. Protein Expr Purif. 2006; 50(1): 43-8[DOI][PubMed]
  • 24. Calder CJ, Liversidge J, Dick AD. Murine respiratory tract dendritic cells: isolation, phenotyping and functional studies. J Immunol Methods. 2004; 287(1-2): 67-77[DOI][PubMed]
  • 25. Yuan JS, Reed A, Chen F, Stewart CN, Jr. Statistical analysis of real-time PCR data. BMC Bioinformatics. 2006; 7: 85[DOI][PubMed]
  • 26. Zhang Y, Zan Y, Shan M, Liu C, Shi M, Li W, et al. Effects of heat shock protein gp96 on human dendritic cell maturation and CTL expansion. Biochem Biophys Res Commun. 2006; 344(2): 581-7[DOI][PubMed]
  • 27. Bolhassani A, Zahedifard F, Taghikhani M, Rafati S. Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies. Vaccine. 2008; 26(26): 3362-70[DOI][PubMed]
  • 28. Li H, Zhou M, Han J, Zhu X, Dong T, Gao GF, et al. Generation of murine CTL by a hepatitis B virus-specific peptide and evaluation of the adjuvant effect of heat shock protein glycoprotein 96 and its terminal fragments. J Immunol. 2005; 174(1): 195-204[PubMed]
  • 29. Mansilla C, Gorraiz M, Martinez M, Casares N, Arribillaga L, Rudilla F, et al. Immunization against hepatitis C virus with a fusion protein containing the extra domain A from fibronectin and the hepatitis C virus NS3 protein. J Hepatol. 2009; 51(3): 520-7[DOI][PubMed]
  • 30. Li B, Pozzi A, Young PP. TNFalpha accelerates monocyte to endothelial transdifferentiation in tumors by the induction of integrin alpha5 expression and adhesion to fibronectin. Mol Cancer Res. 2011; 9(6): 702-11[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments